Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesAsset Writedowns and ImpairmentAsset Writedowns and ImpairmentCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Accured ExpensesChange in Accured ExpensesChange in CashChange in IntangiblesChange in IntangiblesChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresLong-Term Debt IssuancesNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesSales of Property, Plant and EquipmentSales of Property, Plant and EquipmentShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cytosorbents (CTSO) Net Cash Flow (2016 - 2026)

Cytosorbents filings provide 15 years of Net Cash Flow readings, the most recent being -$2.6 million for Q4 2025.

  • On a quarterly basis, Net Cash Flow fell 14.8% to -$2.6 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$3.5 million, a 39.59% increase, with the full-year FY2025 number at -$3.5 million, up 39.59% from a year prior.
  • Net Cash Flow hit -$2.6 million in Q4 2025 for Cytosorbents, down from -$2.5 million in the prior quarter.
  • In the past five years, Net Cash Flow ranged from a high of $5.7 million in Q4 2023 to a low of -$12.7 million in Q2 2022.
  • Median Net Cash Flow over the past 5 years was -$2.9 million (2021), compared with a mean of -$3.2 million.
  • Biggest five-year swings in Net Cash Flow: crashed 340.15% in 2022 and later soared 1137.17% in 2023.
  • Cytosorbents' Net Cash Flow stood at -$7.2 million in 2021, then soared by 92.46% to -$546406.0 in 2022, then soared by 1137.17% to $5.7 million in 2023, then plummeted by 140.55% to -$2.3 million in 2024, then fell by 14.8% to -$2.6 million in 2025.
  • The last three reported values for Net Cash Flow were -$2.6 million (Q4 2025), -$2.5 million (Q3 2025), and -$1.6 million (Q2 2025) per Business Quant data.